You are here

Article info

Article menu

Download PDFPDF

XML
Research Article
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma

Authors

  • Priyanka C. Iyer Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1461 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Ramona Dadu Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1461 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Maria Gule-Monroe Department of Diagnostic Radiology, Division of Diagnostic ImagingThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1482 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Naifa L. Busaidy Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1461 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Renata Ferrarotto Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer MedicineThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 0432 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Mouhammed Amir Habra Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1461 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Mark Zafereo Department of Head and Neck Surgery, Division of SurgeryThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1445 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Michelle D. Williams Department of Pathology, Division of Pathology/Lab MedicineThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 0085 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • G. Brandon Gunn Department of Radiation Oncology, Division of Radiation OncologyProton Therapy Center 1515 Holcombe Blvd, Unit 0097 Houston TX USA PubMed articlesGoogle scholar articles
  • Horiana Grosu Department of Pulmonary Medicine, Division of Internal MedicineThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1462 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Heath D. Skinner Department of Radiation Oncology, Division of Radiation OncologyProton Therapy Center 1515 Holcombe Blvd, Unit 0097 Houston TX USA PubMed articlesGoogle scholar articles
  • Erich M. Sturgis Department of Head and Neck Surgery, Division of SurgeryThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1445 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Neil Gross Department of Head and Neck Surgery, Division of SurgeryThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1445 77030 Houston TX USA PubMed articlesGoogle scholar articles
  • Maria E. Cabanillas Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd, Unit 1461 77030 Houston TX USA PubMed articlesGoogle scholar articles

Citation

Iyer PC, Dadu R, Gule-Monroe M, et al
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
Journal for ImmunoTherapy of Cancer 2018;6:68. doi: 10.1186/s40425-018-0378-y
Online issue publication 
January 09, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.